Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $12.56 | N/A | +53.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $12.56 | N/A | +53.62% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed confidence in the company's performance and future prospects. They highlighted their commitment to innovation and product development.
We are pleased with our strong EPS performance this quarter.
Our focus remains on innovation and expanding our product pipeline.
Regeneron's strong EPS performance indicates effective cost management and possibly strong sales of its products. The stock's 4.25% increase reflects investor optimism following the earnings report. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CATERPILLAR INC
Jan 31, 2023